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http://intl.elsevierhealth.com/journals/ijidThere are many privileges associated with being Editor-in-
Chief of a major international journal, but one particular
pleasure is the opportunity to write a valedictory editorial. I
will shortly be standing down after five highly enjoyable years
as Editor-in-Chief of the International Journal of Infectious
Diseases and this seems like a good time to make some
observations about one of the more controversial areas in
medical publishing.
The notion that publication of research findings is the
‘currency’ of scientific productivity is very well established.
Authors vie for publication in journals with the highest
impact factors for very good reasons: they bring prestige,
influence, money, and promotion. But we should not forget
that arguably the principal reason for publication is commu-
nication — communication as effectively as possible with the
largest number of people, so as to ensure the highest quality
of information is disseminated widely.
It is sometimes easy in these discussions to overlook the
part played by the publishers. They too have an agenda — a
very straightforward agenda of commercial success. ‘Suc-
cessful journals’ have large circulations, attract significant
advertising revenue and supplements, and therefore make
money. It is of course true that reputable and responsible
publishers are certainly interested in ensuring a high quality
product in the sameway that Mercedes-Benz are proud of the
quality of their cars, but neither publishers nor car manu-
facturers can ultimately afford to lose money on their pro-
ducts.
With that as background, let us now consider the current
debate around so-called ‘open access’ publishing. To those
unfamiliar with the issue let me briefly summarize the main
points.
In the conventional model of publishing, the cost of
producing a print journal is borne by the reader who pays
a subscription (either individually or as part of a membership
fee of a society or a professional body). Often the reader does
not pay personally but has his or her access bought on their
behalf by the library in the institution in which they work. By
contrast in the open accessmodel it is the author of the paper1201-9712/$32.00 # 2006 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2006.08.001who pays. Typically, open access journals will charge about
$1500—$2000 to the authors of the paper that they publish.
Once published the paper can then be accessed for free by
anyone, usually over the World Wide Web.
Of course, in both models there are systems established to
mitigate the cost for those who cannot pay. In the conven-
tional model, many publishers have systems to provide a
range of journals to libraries in parts of the world where
resources are few, and in the open access system the point is
always made that where there is genuine financial hardship
the cost of publishing will be reduced or completely
removed. But it is obvious in either model that each of these
systems can only go so far; ultimately the price of these cost
reduction systems must be borne by the revenue from the
bulk of the users of the journals.
So which is the better system? The advent of the open
access model has been widely welcomed as a way of improv-
ing communication while breaking the financial stranglehold
of the conventional publishing companies. The Wellcome
Trust, for instance, has made it obligatory that all grant
holders are required to submit an electronic copy of the final
manuscripts of their research papers into PubMed Central.
Their work will then be made freely available to the public,
via the web, no later than six months after the official date of
final publication.
Publishers like Elsevier (who publish the International
Journal of Infectious Diseases) have argued vociferously
that they offer a high quality service and value for money.
But it is a brutal business: the number of publishers of
science, technology, and medicine journals has rapidly
declined in recent years. Elsevier publishes thirty titles in
infectious diseases and microbiology alone. There is clearly
a danger that the financial muscle that they and other
publishers, such as the Nature Publishing Group, are able
to wield could distort the market and make journals inac-
cessible because of rising cost. That might be fine for the
authors (they would not have to pay to have their papers
published) but not so good for the readers who might have
limited access.Published by Elsevier Ltd. All rights reserved.
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generally will have free access to the journals. But getting
published will be difficult and there are already signs that the
publication fee, for example in the Public Library of Science
(PLoS) journals, is set to rise.
So where does that leave the International Journal of
Infectious Diseases? Our constituency is rather different from
the ‘conventional’ audience for many biomedical journals,
which in the main are directed to readers in first world
countries with substantial resources for science and technol-
ogy. Seventy percent of International Journal of Infectious
Diseases papers are published from areas outside of Europe
and North America. Often the authors of these papers are in a
relatively resource-poor environment and will have difficulty
finding the not insignificant funds required to submit a paper
under the open access model. Conversely, the same clinicians
and scientists, whose libraries are often desperately under-
funded, may welcome the open access model with open arms
because of the enhanced access it will provide.
At the moment, the open access versus conventional
publisher debate is very polarized. I am not certain that
either of these models in the most extreme form is best
suited to the particular interests of the International Journalof Infectious Diseases and the Society. Maybe the way for-
ward for our journal, and perhaps for others, is to explore a
hybrid system that would bring the benefits of wider access
while at the same time starting to break the hegemony of the
publishers and the potentially crippling financial costs of
author-pays publication. An interesting challenge indeed
for the next five years of the journal.
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